Today's Healthcare Pulse
FDA greenlights durvalumab combo for high‑risk bladder cancer
The FDA approved durvalumab (Imfinzi) combined with Bacillus Calmette‑Guerin for BCG‑naïve, high‑risk non‑muscle invasive bladder cancer. The POTOMAC trial enrolled 1,018 patients and showed a 32% reduction in disease recurrence risk (hazard ratio 0.68, p=0.015). Durvalumab is given at 1,500 mg IV every four weeks for up to 13 cycles.
Also developing:
By the numbers: Apogee Therapeutics raises $1.3B royalty financing
Qualtrics Closes $6.75 B Deal for Press Ganey Forsta, Expands Into Healthcare
Qualtrics completed a $6.75 billion acquisition of Press Ganey Forsta, giving it access to more than 41,000 U.S. hospitals and the largest AI‑powered healthcare experience dataset. The deal closed despite a turbulent financing environment that saw a $5.3 billion debt package lose over $500 million on paper.
Why the Ebola Outbreak Is Worrying Public Health Officials
The World Health Organization has declared a Bundibugyo‑strain Ebola outbreak a public health emergency of international concern after 30 confirmed cases in the Democratic Republic of Congo and two in Uganda, with more than 500 suspected infections. The strain lacks...
How Ochsner Turned Telemedicine Into a Hospital Lifeline
Ochsner Health launched its first telemedicine program in 1998 and expanded into tele‑stroke in 2009, laying a 25‑year foundation for virtual care. The system later unified disparate pilots into a centralized, standardized virtual‑care operating model that pairs virtual clinicians with...
CDC Provides Update on Hantavirus Outbreak Linked to M/V Hondius Cruise Ship
On May 18, 2026, the CDC announced that 18 U.S. passengers repatriated from the M/V Hondius cruise ship will remain in a Nebraska quarantine facility until May 31, marking the end of a 21‑day monitoring period. Since disembarkation, three additional...
Bayer's Asundexian Receives FDA Priority Review for Secondary Stroke Prevention
Bayer AG announced that the U.S. FDA has granted priority review to its investigational oral Factor XIa inhibitor Asundexian for secondary stroke prevention. The decision follows positive Phase 3 OCEANIC‑STROKE data that met both efficacy and safety endpoints, positioning the...
BioMarin Drug Acquired in Buyout Misses Goal in Rare Disease Study
BioMarin Pharmaceutical’s BMN 401, an enzyme‑replacement therapy for ENPP1 deficiency, met its primary biochemical endpoint by raising plasma PPi levels but failed the co‑primary skeletal health goal in a Phase 3 trial of 27 children. The miss on clinical benefit and all...
JCR Pharmaceuticals Highlights Preclinical CNS Gene Therapy Data for JUST-AAV Platform at ASGCT 2026
JCR Pharmaceuticals showcased preclinical data for its JUST‑AAV platform at ASGCT 2026, highlighting enhanced central nervous system (CNS) delivery and reduced liver exposure compared with conventional AAV9 vectors. The platform uses transferrin‑receptor‑targeted capsids to cross the blood‑brain barrier, delivering therapeutic...
Malaysia, Singapore Expand Strategic Healthcare Ties
Malaysia and Singapore are deepening strategic healthcare cooperation, covering food‑labelling alignment, faster medical‑device approvals and expanded cross‑border health tourism. Health ministers signed an MOU in Geneva, pledging joint action on non‑communicable diseases and shared public‑wellbeing goals. Malaysia welcomed Singapore’s Medical...
Medtronic, BD Name New Leaders
Medtronic announced that Kweli Thompson, currently president of its cardiac rhythm management division, will become president of the company's neuroscience portfolio on June 1, succeeding Brett Wall, who will depart by Sept. 1 and resign from the MiniMed board in July. Scott Cundy, Medtronic’s...
Commure Raises $70M, Boosting Post-Money Valuation to $7B
Commure, the AI‑enabled healthcare software firm, secured a $70 million financing round, lifting its total capital raised to $750 million and its post‑money valuation to $7 billion. The round was led by General Catalyst with participation from Sequoia Capital, Morgan Stanley and Kirkland...
Lessons Learned From Drug Development Programs in Autism: Implications for Future Programs
The article synthesizes expert insights on why autism drug development has lagged, highlighting the lack of approved therapies for core symptoms and the challenges posed by biological and clinical heterogeneity. It outlines six key learnings, including the need to measure...
OpenBind Unveils Its First AI Model for Drug Discovery
OpenBind, a UK‑led consortium, has published its first AI‑ready dataset and a predictive model for the EV‑A71 2A protease, a target linked to hand, foot and mouth disease. The release includes 699 X‑ray structures and binding‑strength data for 601 compounds,...
Wave Aims for Monthly Dosing with RNA Editing Treatment for AATD
Wave Life Sciences announced an updated read‑out from its early‑stage trial of an RNA‑editing therapy for alpha‑1 antitrypsin deficiency (AATD). The data indicate that the treatment can restore functional protein levels with a dosing schedule that could be moved to...
This Ebola Outbreak Will Be Hard to Contain
The Democratic Republic of Congo confirmed a new Ebola outbreak that has already sickened more than 500 people and killed over 130, spreading to Uganda. The virus is the Bundibugyo strain, which evades standard rapid tests and lacks approved vaccines...
Century Health Raises $5M for CHARM AI Platform to Accelerate Life Sciences Research
Century Health announced an oversubscribed $5 million seed round led by Origin Ventures, bringing its total funding to a strategic level. The company’s CHARM AI platform automates extraction of unstructured electronic health record data with a validated 97% accuracy rate. Over...
Gifthealth Delivers Off-The-Shelf Solution to Deliver MFN Pricing
Gifthealth, the nation’s largest direct‑to‑patient (DTP) partner, announced an off‑the‑shelf solution that enables manufacturers to offer most‑favored‑nation (MFN) pricing within as little as 21 days. The platform, which already handles more than 90% of U.S. DTP volume, supports high‑volume drugs...
Implement AI in the Mid-Cycle of Rev Cycle for the Biggest Return
Methodist Health System partnered with AKASA to embed an AI coding optimizer in its revenue‑cycle mid‑stage, allowing claims to be reviewed before submission. The tool cut payment turnaround from 90‑120 days to 30‑45 days, generating an extra $120,000‑$150,000 per month....
3 in 4 Compromised Healthcare Devices Expose Patient Records, Flare Report Reveals
Flare’s 2026 State of Healthcare Credential Exposure report documents a 33% year‑over‑year surge in compromised healthcare credentials, with nearly three‑quarters of infected devices leaking EHR/EMR logins. The United States accounts for 48% of all healthcare‑related credential logs surfaced on underground...
EndoQuest Advances Multicenter PARADIGM Trial with Completion of Procedures at Baylor St. Luke’s Medical Center
EndoQuest Robotics announced that Baylor St. Luke’s Medical Center has become an active site in its multicenter PARADIGM trial, successfully completing its first robotic endoscopic submucosal dissection (ESD) procedures using the Endoluminal Surgical (ELS) System. The trial, which evaluates safety and...
DNAnexus Scales AI-Driven Capabilities
DNAnexus unveiled a suite of AI‑driven tools that turn massive multi‑omic datasets into enterprise‑grade AI assets. The GenAI‑powered Omics Data Agent lets researchers query complex data with natural language, while the AutoML Assistant promises up to an 80% reduction in...
Nourish Raises $100M Series C to Reverse Chronic Disease with AI-Native Metabolic Clinic
Nourish, the nation’s largest dietitian‑led metabolic health clinic, announced a $100 million Series C round, lifting its total capital to $215 million. The funding, led by Menlo Ventures and joined by a slate of top venture firms, will expand its AI‑native clinic network,...
Validation Studies, Clinician Verification Keep Ambient AI Accurate
Wendy Charles of the University of Denver and Renee Pratt of the University of North Georgia detail a framework of safeguards that health systems can deploy to keep ambient AI‑generated clinical notes accurate. Their recommendations stress rigorous validation studies, mandatory...
More Good News for Boston Scientific’s Coronary IVL Tech
Boston Scientific reported strong early results from its single‑arm FRACTURE trial of the Seismiq 4CE coronary intravascular lithotripsy (IVL) catheter. Freedom from major adverse cardiac events at 30 days was 93.3%, well above the 86.2% target, and procedural success hit 93.7%...
How Rwanda Is Using Drones to Improve Health Care
In 2016 Rwanda partnered with Zipline to launch drone ports that deliver blood products to hospitals, turning multi‑hour trips into 15‑60‑minute drops. A Wharton‑led study shows the program cut postpartum hemorrhage deaths by 51% and trauma deaths by 30%, while...
How LIMS Supports GMP Compliance
Laboratory Information Management Systems (LIMS) are transitioning from simple workflow tools to essential infrastructure for Good Manufacturing Practice (GMP) compliance across regulated sectors such as pharma, medical devices, cannabis and nicotine products. By embedding audit trails, electronic signatures, version control...
Anthropic’s Mythos Threatens Healthcare Cybersecurity: 6 Updates
Anthropic’s Claude Mythos preview can autonomously discover and exploit zero‑day vulnerabilities across major operating systems and browsers, a leap in AI‑driven cybersecurity. Researchers found thousands of previously unknown flaws before the model’s restricted release, and even users with limited training...
The Bill That Never Ends
Jeni Rae Peters, a single mother with employer‑provided insurance, accrued at least $30,000 in medical debt while treating stage‑2 breast cancer, illustrating how high‑deductible plans can bankrupt patients even when they are covered. A 2024 American Cancer Society survey found...
HCA Florida Hospital Names CEO
HCA Healthcare appointed Philip Marchesini as CEO and market lead of HCA Florida Fawcett Hospital in Port Charlotte. Marchesini previously led HCA Florida Northside Hospital and held COO roles at Largo and St. Peterburg facilities. He succeeds Michael Ehrat, who moves...
Emory Launches ED Nurse Residency Program
Emory Decatur Hospital has launched the health system’s first emergency department nurse residency, the inaugural Emergency Nurses Association program in the Atlanta region. The year‑long curriculum blends clinical education, bedside training and mentorship, beginning with a 16‑week orientation that includes...
Re: UK Alcohol Deaths Fall for First Time Since Pandemic, but Experts Highlight “Stark Inequalities”
UK alcohol‑specific deaths fell for the first time since the pandemic, yet they remain above pre‑COVID levels. The decline masks stark socioeconomic gaps: men in the most deprived neighborhoods are four times more likely to die from alcohol than those...
13 Healthcare Organizations Moving to Epic
Epic solidified its dominance in the U.S. acute‑care EHR market in 2024, capturing 42.3% of hospitals and 54.9% of beds. The KLAS report shows the vendor added a record net gain as ten health systems selected Epic for 108 hospitals,...
Virginia Health System Names New Chief Digital Officer
Centra Health announced Sanjeev Sah as its senior vice president and chief digital and information officer, a role that will steer the Virginia‑based system’s IT and digital transformation. Sah, who posted the news on LinkedIn on May 19, brings experience as...
20 Large Health Systems Growing Bigger
Hospital consolidation is gaining momentum after a brief post‑pandemic pause, with large health systems pursuing cross‑state mergers, acquisitions and strategic partnerships. Twenty major systems announced or plan deals this year, ranging from Atrium Health’s combination with WakeMed to Sutter Health’s...
Hospitals Freeze Jobs in April
Hospital employment stalled in April, with the Bureau of Labor Statistics reporting zero net hires— the first flat month since June 2021. Seasonal adjustments modestly added 4,300 positions, but the broader healthcare sector still created 37,000 jobs, driven by nursing...
Brain Scans Reveal How Ibogaine Alters Neural Networks in Veterans with Head Trauma
Researchers at Stanford reported that a single dose of ibogaine, combined with magnesium, produced measurable neurobiological changes in 30 combat veterans with mild‑to‑moderate traumatic brain injury and PTSD. Functional MRI scans revealed sustained increases in cerebral blood flow across the...
NHS Bill Paves Way for Single Patient Record
The UK Health Bill introduces a nationwide single patient record, obligating hospitals, GPs and other NHS providers to share full medical histories in real time. The legislation also abolishes NHS England, moving its functions to the Department of Health and...
Contractors Lined up for Specific New Hospital Programme Jobs
The NHS has earmarked ten contractors for the first £15 bn wave of its New Hospital Programme under the Hospital 2.0 Alliance framework. The list includes Graham for Airedale, Willmott Dixon for Royal Cornwall, Sacyr UK for Frimley Health, and others, with...
Aetna’s Chief Digital and Technology Officer on How the Insurer Is Using AI for Patient Engagement
Aetna, owned by CVS Health, has launched a conversational AI assistant and a condition‑specific product called Care Paths to simplify member navigation of benefits and care. The AI tools provide natural‑language answers, map providers, and suggest next‑best actions, while also...
Address Clinical and IT Needs First to Help Ensure Ambient AI Success
Wendy Charles of the University of Denver and Renee Pratt of the University of North Georgia warn that while ambient AI can dramatically speed clinical documentation, it also raises accuracy and integration challenges. They argue that success hinges on addressing...
EMA Marketing Authorization of New Drugs in April 2026
In April 2026 the European Medicines Agency granted marketing authorizations and CHMP positive opinions for a slate of new therapies spanning infectious disease, neurology, immunology, endocrinology and rare disorders. Merck’s Enflonsia monoclonal antibody reduced RSV‑related hospitalizations by 84% in infants,...
FDA Approves Eli Lilly’s Foundayo, Pitting First Oral Obesity Pill Against Novo Nordisk’s Wegovy
Eli Lilly’s oral obesity medication Foundayo received FDA approval on April 1, becoming the first pill of its kind and setting up an immediate head‑to‑head battle with Novo Nordisk’s oral Wegovy. The two drugs differ in efficacy, manufacturing ease and safety profile,...
ACA Deductibles Surge $1,000 as Subsidies End
New: The average ACA deductible has jumped by over $1,000 per person in 2026 as people switched to lower premium plans with higher deductibles as Congress allowed enhanced premium subsidies to expire.
Everyone’s Betting on AI to Solve the Physician Shortage —They’re Solving the Wrong Problem
The U.S. healthcare debate frames physician shortages as a supply issue, prompting more residency slots and medical‑school expansions. Recent McKinsey and Deloitte surveys, however, show that the real constraint is distribution—administrative friction keeps trained doctors from working where needed. About...
Accro Bioscience Secures $50 Million Series C Led by OrbiMed to Advance Ulcerative Colitis Drug
Accro Bioscience announced a $50 million Series C round headed by OrbiMed, with participation from TCGX, LAV, Cenova Capital and existing backers. The capital will finance a Phase IIb study of AC-101, a RIPK2 inhibitor targeting ulcerative colitis, underscoring private‑equity interest...
Lus Essentials LLC - 728783 - 05/14/2026
The FDA issued a warning letter to Lus Essentials LLC on May 14, 2026 after laboratory analysis revealed that its skin‑treatment products contain high levels of mercury. The agency classified the items as unapproved new drugs and misbranded drugs under...
La Crema De Rebeca - 728782 - 05/14/2026
The FDA issued a warning letter to La Crema De Rebeca after laboratory analysis revealed high mercury levels in its skin‑treatment cream. The agency classified the product as an unapproved new drug and a misbranded drug because its labeling omitted...
JW Nutritional LLC - 722096 - 04/15/2026
The FDA issued a Warning Letter to JW Nutritional LLC after a September 2025 inspection uncovered multiple CGMP violations at its McKinney, Texas facility. The firm failed to perform identity testing on incoming high‑risk components, lacked validated process controls, and...
Harbin Jixianglong Biotech Co., Ltd. - 723330 - 05/01/2026
The FDA issued a warning letter to Harbin Jixianglong Biotech after a November 2025 inspection revealed multiple CGMP violations involving its peptide API manufacturing. The firm repackaged and relabeled semaglutide batches from unapproved suppliers, misbranding the products and failing to...
PolleyMed, LLC - 726018 - 05/14/2026
The FDA issued a warning letter to PolleyMed, LLC for marketing its SaniiSwab™ nasal cleaning product as an unapproved new drug and for misbranding claims of FDA OTC approval. The agency’s review of the company’s website and social‑media content found...
Sourav K. Mishra, M.D. / All India Institute of Medical Sciences - 724881 - 04/29/2026
The FDA issued a warning letter to Dr. Sourav K. Mishra of AIIMS Bhubaneswar for serious violations in a bioequivalence study of doxorubicin hydrochloride liposome injection conducted for Qilu Pharmaceutical. The investigator administered the prohibited CYP3A4 inhibitor aprepitant to all...